PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 32–32 | Cite as

Secukinumab cost effective in active psoriatic arthritis in Finland

Clinical study


  1. Purmonen T, et al. Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Cost Effectiveness and Resource Allocation : 16 Nov 2018. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations